CGEM Cullinan Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CGEM

Price (delayed)

$19.64

Market cap

$1.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.11

Enterprise value

$1.19B

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7
Highlights
The EPS is up by 8% since the previous quarter and by 2.2% year-on-year
CGEM's net income is up by 7% from the previous quarter
The debt is up by 36% year-on-year but it has declined by 13% since the previous quarter
Cullinan Oncology's equity has decreased by 35% YoY and by 12% from the previous quarter
CGEM's quick ratio is down by 18% from the previous quarter and by 13% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cullinanoncology.com

Key stats

What are the main financial stats of CGEM

CGEM stock price

How has the Cullinan Oncology stock price performed over time
Intraday
0.2%
1 week
9.42%
1 month
9.9%
1 year
157.07%
YTD
89.76%
QTD
7.85%

Financial performance

How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$221.81M
Net income
-$204.69M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 8% from the previous quarter and by 5% YoY
CGEM's net income is up by 7% from the previous quarter

Price vs fundamentals

How does CGEM's price correlate with its fundamentals

Growth

What is Cullinan Oncology's growth rate over time

Valuation

What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
3.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 8% since the previous quarter and by 2.2% year-on-year
The price to book (P/B) is 168% higher than the 5-year quarterly average of 1.4 and 88% higher than the last 4 quarters average of 2.0
Cullinan Oncology's equity has decreased by 35% YoY and by 12% from the previous quarter

Efficiency

How efficient is Cullinan Oncology business performance
CGEM's return on invested capital has dropped by 58% year-on-year and by 6% since the previous quarter
Cullinan Oncology's return on equity has decreased by 45% YoY and by 2.9% QoQ
The company's return on assets fell by 38% YoY

Dividends

What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CGEM.

Financial health

How did Cullinan Oncology financials performed over time
The total liabilities has increased by 49% year-on-year and by 14% since the previous quarter
CGEM's total assets is down by 30% year-on-year and by 10% since the previous quarter
The debt is 99% smaller than the equity
The debt is up by 36% year-on-year but it has declined by 13% since the previous quarter
Cullinan Oncology's equity has decreased by 35% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.